Tag Archives: GLP-1 Agonists

For many people living with type 2 diabetes, treatment eventually reaches a frustrating crossroads. Despite multiple medications, including GLP-1 receptor agonists, SGLT2 inhibitors, and insulin, glycemic targets may remain difficult to achieve. Meanwhile, bariatric surgery can produce major metabolic benefits, but its invasiveness limits acceptance for many patients. This treatment …

Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …

A patient starts semaglutide through a telehealth platform, receives nutrition advice from a wellness clinic, and later visits a primary care physician for worsening gastrointestinal symptoms. None of the providers can see the full treatment picture. Situations like this are becoming increasingly common as GLP-1 medications move across multiple corners …

Managing post-meal glucose levels plays a critical role in diabetes care, yet it is often overlooked in favor of A1C and time in range. However, what happens after meals can significantly affect long-term outcomes. Think of it like traffic flow: even if the highway looks clear overall, sudden congestion at …

Disease progression in patients using GLP-1 therapies is becoming a critical topic as these medications continue to reshape diabetes care. While GLP-1 receptor agonists improve glycemic control and support weight loss, could they also be hiding deeper metabolic decline? Much like a polished surface that conceals underlying cracks, improved lab …

Patients who do not respond to GLP-1 therapy are becoming a growing concern in diabetes care, especially as GLP-1 receptor agonists continue to gain popularity for glycemic control and weight management. While clinical trials often show strong benefits, real-world results can vary. So why do some patients fail to respond …

Concerns about GLP-1 drug interactions are rising as these therapies gain widespread use in diabetes and obesity management. As more patients start medications like semaglutide and liraglutide, clinicians are asking an important question: how do these drugs affect the absorption of other treatments? Much like slowing traffic on a busy …

The CKM framework in diabetes care—focusing on cardiovascular, kidney, and metabolic health—is more than a trend. It’s a clinical necessity. The ADA’s 2025 Standards of Care urge clinicians to manage these overlapping risks together, not separately. Why? Because patients with diabetes deserve outcomes that go beyond just A1C. This article …

Living with type 2 diabetes often means managing more than just blood glucose. For many patients, conditions like cardiovascular disease, chronic kidney disease, or depression take center stage in their care plan. When diabetes isn’t the main problem, how do you keep glucose control on track without compromising treatment for …

GLP-1 agonists are a class of drugs used to treat type 2 diabetes and obesity. They work by stimulating the release of glucagon-like peptide-1 (GLP-1), a hormone that helps regulate blood sugar levels and appetite. In recent years, the efficacy of GLP-1 agonists has been evaluated in clinical trials, providing …